GlaxoSmithKline reports positive Phase I trial results of Ebola vaccine candidate
The new vaccine candidate was co-developed by the National Institutes of Health’ (NIH) National Institute of Allergy and Infectious Diseases (NIAID) and Okairos, a biotechnology firm acquired by
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.